Chemed Is Maintained at Outperform by RBC Capital

Chemed Is Maintained at Outperform by RBC Capital

Dow JonesMay 21 23:04

Royal Bank of Canada: Maintaining the Chemed (CHE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $712.00 to $697.00.

Royal Bank of Canada: Maintaining the Chemed (CHE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $712.00 to $697.00.

Zhitong FinanceMay 21 23:02

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $697

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $712 to $697.

BenzingaMay 21 22:56

Chemed Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 23.98% RBC Capital $712 → $697 Maintains Outperform 03/04/2024 26.65% RBC Capital $604 → $712 M

BenzingaMay 21 22:53

Analysts Are Bullish on Top Healthcare Stocks: Hookipa Pharma (HOOK), Chemed (CHE)

TipRanksMay 21 19:01

Chemed To Go Ex-Dividend On May 30th, 2024 With 0.4 USD Dividend Per Share

May 21st - $Chemed(CHE.US)$ is trading ex-dividend on May 30th, 2024. Shareholders of record on May 30th, 2024 will receive 0.4 USD dividend per share on June 18th, 2024. The ex-dividend date is M

Futu NewsMay 21 07:40